Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
redness; swelling; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of erythema in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On 05-AUG-2025, the patient received Menveo. In AUG-2025, less than a week after receiving Menveo, the patient experienced erythema (Verbatim: redness) and swelling (Verbatim: swelling). The outcome of the erythema and swelling were unknown. It was unknown if the reporter considered the erythema and swelling to be related to Menveo. It was unknown if the company considered the erythema and swelling to be related to Menveo. Additional Information: GSK Receipt Date: 08-AUG-2025 The pharmacy buyer reported about a potential reaction to Menveo and the patient had the readiness and swelling. No more information at this time and said will fill out additional report once more information is obtained This case is linked with US2025102720, by the same reporter; Sender's Comments: US-GSK-US2025102720:Diffrent patient